ViaCyte's potential diabetes 'cure' gets another $6m to move into human trials
This article was originally published in Clinica
Executive Summary
ViaCyte's stem cell-based diabetes product, which the San Diego-based company has said could reduce or eliminate the need for pharmaceutical insulin, has moved into clinical trials earlier than expected, helped by $6 million in new funds. This brings the total invested by the Juvenile Diabetes Research Foundation (JDRF) to $7 million, while the California Institute for Regenerative Medicine (CIRM) has financed nearly $40 million in preclinical work for the VC-01 therapeutic and device combination product.
You may also be interested in...
Sanofi Clinches Key Phase III Immunology Win With Rilzabrutinib
Sanofi’s BTK inhibitor – one of two from its 2021 Principia buy – passed a Phase III test in immune thrombocytopenia as the company focuses on Dupixent-like blockbusters going forward.
Ipsen Expands Its Rare Neurological Disease Pipeline With Skyhawk Deal
Deal Snapshot: Ipsen committed up to $1.8bn in upfront and milestone fees to develop novel treatments for rare neurological diseases with Skyhawk’s RNA-targeting small molecule platform.
Finance Watch: Canaan, Regeneron Reveal New Funds For Start-Ups
Private Company Edition: Regeneron launched a $500m venture fund and Canaan added $100m, bringing the venture firm’s recent total to $1bn-plus. Also, incubators plan to grow over the next decade and in recent financings Avenzo raised $150m and Nvelop launched with $100m.